清瘀温通方治疗子宫腺肌病痛经的临床疗效

夏馨; 杜尘; 庄梦斐; 王唯迪; 曹阳; 张婷婷

doi:10.16306/j.1008-861x.2021.06.006

您当前的位置：

首页 >

文章列表页 >

清瘀温通方治疗子宫腺肌病痛经的临床疗效

临床研究 | 更新时间：2022-09-09

- 清瘀温通方治疗子宫腺肌病痛经的临床疗效
- Clinical efficacy of Qingyu Wentong Formula in the treatment of dysmenorrhea due to adenomyosis
- 上海中医药大学学报 2021年35卷第6期页码：37-41
- 作者机构：
  
  1.上海市静安区中医医院（上海　200047）
  2.上海中医药大学附属岳阳中西医结合医院（上海　200437）
- 作者简介：
  
  夏馨，女，硕士，住院医师，主要从事中西医结合治疗妇科疾病的临床研究
  曹阳，副主任医师；E-mail：cindy8813966@126.com
- 基金信息：
  
  国家自然科学基金面上项目(82074475);上海市科委科研计划项目(18401972000);上海市“十三五”临床重点专科建设项目(shslczdzk04501);上海市静安区卫计委科研项目(2019ZY04)
- DOI：10.16306/j.1008-861x.2021.06.006
  中图分类号：
扫描看全文
夏馨, 杜尘, 庄梦斐, 等. 清瘀温通方治疗子宫腺肌病痛经的临床疗效[J]. 上海中医药大学学报, 2021,35(6):37-41.

XIA Xin, DU Chen, ZHUANG Mengfei, et al. Clinical efficacy of Qingyu Wentong Formula in the treatment of dysmenorrhea due to adenomyosis[J]. Academic Journal of Shanghai University of Traditional Chinese Medicine, 2021,35(6):37-41.
夏馨, 杜尘, 庄梦斐, 等. 清瘀温通方治疗子宫腺肌病痛经的临床疗效[J]. 上海中医药大学学报, 2021,35(6):37-41. DOI： 10.16306/j.1008-861x.2021.06.006.

XIA Xin, DU Chen, ZHUANG Mengfei, et al. Clinical efficacy of Qingyu Wentong Formula in the treatment of dysmenorrhea due to adenomyosis[J]. Academic Journal of Shanghai University of Traditional Chinese Medicine, 2021,35(6):37-41. DOI： 10.16306/j.1008-861x.2021.06.006.

摘要

目的：,2,观察清瘀温通方治疗子宫腺肌病痛经患者的临床疗效及对相关炎症因子的影响。,方法：,2,纳入子宫腺肌病痛经患者62例，采用随机数字表分为治疗组32例和对照组30例。治疗组患者给予清瘀温通方口服治疗，对照组患者给予散结镇痛胶囊口服治疗，治疗周期为3个月经周期。评价并比较两组患者的痛经改善疗效；采用视觉模拟评分法（VAS）评价患者的痛经疼痛程度；检测两组患者的血清糖类抗原125（CA125）、超敏C反应蛋白（hs-CRP）、白介素-6（IL-6）、单核细胞趋化蛋白-1（MCP-1）的水平。,结果：,2,①治疗后，治疗组患者的痛经改善疗效总有效率为84.38%，对照组为60.00%，治疗组的疗效优于对照组（,P,<,0.05）。②治疗后，两组患者的痛经疼痛VAS评分较治疗前均显著下降（,P,<,0.01），但两组间评分比较，差异无统计学意义（,P,>,0.05）。③治疗后，两组患者的hs-CRP、IL-6、MCP-1水平较治疗前均降低（,P,<,0.05），治疗组患者的CA125水平较治疗前亦降低（,P,<,0.05），且治疗组患者的CA125、hs-CRP、IL-6、MCP-1水平低于对照组（,P,<,0.05）。,结论：,2,清瘀温通方可明显减轻子宫腺肌病患者的痛经症状，其机制可能与抑制血清促炎细胞因子的产生、减轻炎症反应及改善子宫内环境微炎症状态有关。

Abstract

Objective:,2,To observe the clinical efficacy of Qingyu Wentong Formula in treating patients with dysmenorrhea due to adenomyosis and its influence on the related inflammatory factors.,Methods:,2,A total of 62 patients with dysmenorrhea due to adenomyosis were included and divided into the treatment group(32 cases) and control group(30 cases) by random number table.The patients in the treatment group were orally treated with Qingyu Wentong Formula, and the patients in the control group were orally treated with Sanjie Zhentong Capsule.The treatment course was 3 menstrual cycles.The improvement efficacy on dysmenorrhea in both groups was evaluated and compared, the pain degree of dysmenorrhea was evaluated by visual analogue scale(VAS), and the serum levels of carbohydrate antigen 125(CA125), high sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6) and monocyte chemoattractant protein-1(MCP-1) were detected.,Results:,2,①After treatment, the total effective rate of dysmenorrhea improvement was 84.38% in the treatment group and 60.00% in the control group, and the efficacy of the treatment group was better than that of the control group(,P,<,0.05) .②After treatment, the VAS score of dysmenorrhea pain in both groups was significantl decreased compared with that before treatment(,P,<,0.01), but there was no statistically significant difference on the score between the two groups(,P,>,0.05) .③After treatment, the levels of hs-CRP, IL-6 and MCP-1 in both groups were decreased compared with those before treatment(,P,<,0.05), the level of CA125 in the treatment group was also decreased compared with that before treatment(,P,<,0.05), and the levels of CA125, hs-CRP, IL-6 and MCP-1 in the treatment group were lower than those in the control group(,P,<,0.05) .,Conclusion:,2,Qingyu Wentong Formula can significantly reduce the symptoms of dysmenorrhea in patients with adenomyosis, and its mechanisms may be related to inhibiting the production of serum proinflammatory cytokines, reducing inflammatory reaction and improving the micro-inflammatory status of uterine environment.

关键词

子宫腺肌病痛经清瘀温通方炎症因子

Keywords

adenomyosisdysmenorrheaQingyu Wentong Formulainflammatory factor

references

ZOU Y，LIU F Y，WANG L Q, et al. Downregulation of DNA methyltransferase 3 alpha promotes cell proliferation and invasion of ectopic endometrial stromal cells in adenomyosis[J]. Gene，2017，604：41-47.

丰慧洁，郑瑞君.中医药治疗子宫内膜异位症研究概况[J].国医论坛，2021，36(2)：72-75.

中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊治指南[J].中华妇产科杂志，2015，50(3)：161-169.

罗颂平.中医妇科学[M].北京：高等教育出版社, 2008:260-262.

郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社, 2002:381-385.

NELSEN L M，LENDERKING W R，POKRZYWINSKI R, et al. Experience of symptoms and disease impact in patients with adenomyosis[J]. Patient，2018，11(3)：319-328.

陈倩，李蕴薇，王姝，等.子宫腺肌症患者临床特点回顾性分析[J].生殖医学杂志，2021，30(2)：150-155.

中国医师协会妇产科医师分会子宫内膜异位症专业委员会.子宫腺肌病诊治中国专家共识[J].中华妇产科杂志，2020，55(6)：376-383.

MARUYAMA S，IMANAKA S，NAGAYASU M, et al. Relationship between adenomyosis and endometriosis; Different phenotypes of a single disease？[J]. Eur J Obstet Gynecol Reprod Biol，2020，253：191-197.

卢利霞，边文会.中西医治疗子宫腺肌病研究进展[J].河北中医药学报，2019，34(3)：54-58.

徐英，付金荣.活血化瘀法治疗子宫内膜异位症的研究进展[J].中医文献杂志，2019，37(4)：71-73.

李爽爽，曹阳，张婷婷，等.子宫内膜异位症寒热辨证相关因素的比较研究[J].上海中医药大学学报，2020，34(2)：31-36.

束兰娣，张婷婷，陈静，等.红藤方在妇科痛证方面的应用[J].中华现代中医学杂志，2010，6(4)：238-240.

张婷婷，陈麒，朱抗美，等.中药“红藤方”对子宫内膜异位症模型大鼠异位内膜的形态学影响[J].生殖与避孕，2005，25(12)：716-719,737.

杨峰，李凤梅.红藤方治疗子宫内膜异位症82例临床观察[J].山东中医杂志，2006，25(12)：824-825.

伍娟娟，何嘉，邓海婷，等.基于网络药理学探讨失笑散治疗子宫内膜异位症痛经的作用机制研究[J].世界科学技术-中医药现代化，2019，21(11)：147-156.

姚楠，王志旺，付晓艳，等.当归挥发油及其苯酞类成分对平滑肌作用的研究进展[J].中国现代应用药学，2019，36(21)：2738-2742.

王金金，毋启桐，时博，等.小茴香炮制历史沿革、化学成分及药理作用研究进展[J].中国实验方剂学杂志，2020，26(20)：178-190.

魏竞男，王爱丽，陈彦，等.黄芪健脾益气汤治疗子宫腺肌病气虚血瘀证的临床研究[J].中医药导报，2017，23(23)：91-93.

中国中西医结合学会妇产科专业委员会.子宫内膜异位症中西医结合诊治指南[J].中国中西医结合杂志，2019，39(10)：1169-1176.

苏家林，张赟，卢朝霞，等.中性粒细胞/淋巴细胞比值、血清CA125及CA199检测在子宫腺肌病和子宫内膜异位症中的临床意义[J].中国当代医药，2021，28(1)：132-134,138.

SHETH S S，RAY S S. Severe adenomyosis and CA125[J]. J Obstet Gynaecol，2014，34(1)：79-81.

郑振丽，高玉青，韩宁.桂枝茯苓丸联合左炔诺孕酮宫内节育系统治疗子宫腺肌症的疗效及其对血清VEGF、CA125水平的影响[J].上海中医药杂志，2019，53(7)：52-55,65.

ORAZOV M R，RADZINSKY V E，NOSENKO E N, et al. Immune-inflammatory predictors of the pelvic pain syndrome associated with adenomyosis[J]. Gynecol Endocrinol，2017，33(Sup1)：44-46.

MOSELE S，STRATOPOULOU C A，CAMBONI A, et al. Investigation of the role of platelets in the aetiopathogenesis of adenomyosis[J]. Reprod Biomed Online，2021，42(4)：826-834.

孙小军.瑞舒伐他汀对冠心病病人血清炎症因子、血脂及凝血功能的影响[J].中西医结合心脑血管病杂志，2017，15(23)：3035-3038.

寇晋丽，杨潇，林云，等.坤泰胶囊对于慢性盆腔炎不孕女性抗炎作用及卵巢储备功能的影响[J].世界中西医结合杂志，2020，15(7)：1319-1322,1326.

BOURDIEC A，AHMAD S F，LACHHAB A, et al. Regulation of inflammatory and angiogenesis mediators in a functional model of decidualized endometrial stromal cells[J]. Reprod Biomed Online，2016，32(1)：85-95.

GORI I，PELLEGRINI C，STAEDLER D, et al. Tumor necrosis factor-α activates estrogen signaling pathways in endometrial epithelial cells via estrogen receptor α[J]. Mol Cell Endocrinol，2011，345(1-2)：27-37.

乔海风，刘颖蕾，鲁晓燕，等.巨噬细胞CD68、IL-6在子宫腺肌病组织中表达的研究[J].中华临床医师杂志（电子版），2014，8(17)：3102-3106.

AHN S H，KHALAJ K，YOUNG S L, et al. Immune-inflammation gene signatures in endometriosis patients[J]. Fertil Steril，2016，106(6)：1420-1431.

SIKORA J，SMYCZ-KUBANSKA M，MIELCZAREK-PALACZ A, et al. Abnormal peritoneal regulation of chemokine activation—The role of IL-8 in pathogenesis of endometriosis[J]. Am J Reprod Immunol，2017，77(4)：e12622.

王华，李庭芳.VEGF、TGF-β1、MCP-1在子宫腺肌病中的表达及临床意义[J].新疆医科大学学报，2005，28(6)：564-567.

WAIYAPUT W，PUMIPICHET S，WEERAKIET S, et al. Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial[J]. BMC Womens Health，2017，17(1)：89.

周围，佘立平，纪亚忠，等.MCP-1、HGF、TGF-β1在子宫内膜异位症中的表达及意义[J].同济大学学报（医学版），2015，36(1)：63-66.

浏览量

434

下载量

CSCD

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

艾灸督脉治疗脑梗死恢复期临床疗效观察

蔡小荪教授辨治痛经探微